Last reviewed · How we verify

NCT06187051

Type 1 Endoleak : Fenestrated Custom Made Endograft (FEVAR) Versus Open Surgery Explantation (OSR) : What's the Best

Completed Last updated 10 January 2024
What this trial tests

trial testing FEVAR in Aorta Aneurysm in 200 participants. Completed in 1 December 2023.

Timeline
1 January 2010
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorUniversity Paul Sabatier of Toulouse
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date1 January 2010
Primary completion1 December 2023
Estimated completion1 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

University Paul Sabatier of Toulouse

Who can join

Eligibility, any sex, with Aorta Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Proximal type 1A endoleak is a worrying complication after endovascular repair of an abdominal aortic aneurysm (EVAR). The ideal solution is not obvious between relining by FEVAR and endograft explantation. A retrospective french multicentric study was performed between 2010 and 2023 to compare the outcomes and the efficiency of both technics and propose a decision algorithm for the management of type 1A endoleak after EVAR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Aorta Aneurysm

Currently open trials in the same condition.

Other University Paul Sabatier of Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06187051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing